Corsee Sanders is currently serving as EVP and Strategic Advisor to the CMO of Celgene Corp. Prior to Celgene’s acquisition of Juno Therapeutics, she was on the Executive Committee of Juno, serving as Executive Vice President, Strategic and Development Operations since January 2017. She was responsible for the portfolio leadership and management, strategic operations, patient and clinical operations, and biometrics. Prior to joining Juno, Dr. Sanders was Senior Vice President and Head of Global Clinical Operations and Industry Collaborations at Roche Pharmaceuticals, where she also served as Head of Global Biometrics and Development Innovation. Previously, she worked in a number of senior leadership roles at Genentech, Inc., where she was instrumental in the development of some of Genentech’s most successful products, including Herceptin and Avastin. At Genentech, her responsibilities covered a range of functions, including biostatistics, epidemiology, health economics and outcomes research, data management, medical writing, information technology, and biosample management. Dr. Sanders holds bachelor’s and master’s degrees in statistics from the University of the Philippines, and received a master’s degree and doctorate in statistics from the Wharton School at the University of Pennsylvania.